What's hot
View all perspectives
For many years glucocorticoids were the mainstay of our treatment of granulomatosis with polyangiitis (GPA). The paradigm shifted with cyclophosphamide and then again with rituximab, and we used less steroids, but we still used lots. Avacopan teased the demise of steroids, but in the trial they, and now we, still use them. Glucocorticoids are our old trusty friend, our comfort blanket. But no more! Good riddance to the medication with the
Akhil Sood MD AkhilSoodMD
9 months 4 weeks ago
Can multidisciplinary clinics improve quality of care for PsA?
Abstract 0596: Multidisciplinary care in PsA associated with ↓ time to first biologic, ↑ dermatology & nurse visits, and better CV risk assessment. #ACR24 @RheumNow https://t.co/2OnUR6te63
Richard Conway RichardPAConway
9 months 4 weeks ago
Pasoto et al. Holding MMF for 1 week after zoster vaccine (RZV) improves response with no increase in flare @RheumNow #ACR24 Abstr#0247 https://t.co/q757bMFp7I https://t.co/rwjz3q3MaO
Eric Dein ericdeinmd
9 months 4 weeks ago
Pharmacologics:
Cannabis absorption and metabolism is variable
Inhaled absorption 10-35%
THC is 97% protein bound, lipophilic and deposits in fat and spleen
Liver function is critical for THC metabolism
16S18 @BharatKumarMD
#ACR24 @RheumNow
Richard Conway RichardPAConway
9 months 4 weeks ago
Quinn @KQuinnRheum @petercgrayson et al. FDG-PET is not particularly useful in monitoring GCA on tocilizumab. Toc reduces but often not eliminate PET inflammation. PET activity does not predict relapse or vascular progression @RheumNow #ACR24 Abstr#0742 https://t.co/1qcJCGV118 https://t.co/6mBCgcbYo6
Mike Putman EBRheum
9 months 4 weeks ago
Prevalence of HLH among pts w/SLE: lower than consults would suggest!
Observational study using NIS: 139 cases out of >100k pts w/SLE (0.13%); 6 fold increase in mortality
Fits my priors; HLH is overdiagnosed, but bad when it happens
@RheumNow #ACR24 Abstr#0619 https://t.co/iz3BlUOJb9
Akhil Sood MD AkhilSoodMD
9 months 4 weeks ago
#Abstract0649
Acetylated albumin at K402 as a possible predictor for newly diagnosed lupus nephritis, distinguishing incident LN from SLE, treated LN & healthy controls.
@RheumNow #ACR24 https://t.co/aCRzt9TtoK
Richard Conway RichardPAConway
9 months 4 weeks ago
Harkins @DrTrishHarkins et al. Serum disease activity markers in PMR. ROC analysis for active vs remission - fibrinogen (1.000), ESR (0.986), Haptoglobin (0.976), CRP (0.986), ALP (0.854). @RheumNow #ACR24 Abstr#0741 https://t.co/f8cX68Ov9Y https://t.co/zp5c7aQwxr
Caoilfhionn Connolly CaoilfhionnMD
9 months 4 weeks ago
#0066
🧬Epigenetics, Gut Microbiota & RA
🔬 110 RA patients v 110 controls
🦠 Collinsella abundance a/w DNA methylation changes (PRHOXNB, TBC1D22A) in RA, correlating with disease activity.
💡❔Role of gut microbiota & epigenetic markers as RA biomarkers
#ACR24 @RheumNow https://t.co/yZn0KkRpE6
Adela Castro AdelaCastro222
9 months 4 weeks ago
Is biologic response different in men vs women with axSpA?
A Meta-analysis of 11 studies including 11,199 axSpA pts evaluated sex-related response to bDMARDs
-Male pts more likely to achieve BASDAI 50 and ASDAS low disease activity responses compared to females.
#Abst0599… https://t.co/FopBLS4bF6 https://t.co/PpoZB9HwZN
Richard Conway RichardPAConway
9 months 4 weeks ago
Dunn et al. Are the medications recommended for RA-ILD by the ACR guidelines used in the real-world. NO! 4108 RA-ILD patients. Only 12% on one of the first line recommended therapies! @RheumNow #ACR24 Abstr#0214 https://t.co/OzW90OA1Vd https://t.co/S1MKmEDrLF
Antoni Chan MD (Prof) synovialjoints
9 months 4 weeks ago
The METEOR study reveals distinct clinical features in spondyloarthritis (SpA) patients with vs. without IBD.
Key features of those with IBD:
- Lower male prevalence
- Higher uveitis rates
- Lower psoriasis rates
- More structural damage in SI joints
Mirroring gut… https://t.co/EyBZQ91DDn
Akhil Sood MD AkhilSoodMD
9 months 4 weeks ago
Another abstract #0650 highlighting the impact of tubulointerstitial inflammation predicting risk of CKD/ESRD in lupus nephritis
@RheumNow #ACR24 https://t.co/XYwO0xnWNR
Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A and F. There have been more updates on the 2 year data on BKZ at #ACR24, and this is a summary of four studies being presented this year at ACR24.
Dr. John Cush RheumNow
9 months 4 weeks ago
RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty.
Poster Hall